Compare Abbott Laboratories (ABT) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Lockheed Martin Corporation — how do they compare? Abbott Laboratories trades at $95.76 (market cap $166.94B), while Lockheed Martin Corporation trades at $530.3 (market cap $123.44B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | LMT | |
|---|---|---|
Market Cap | $166.94B | $123.44B |
Sector | Health | Industrials |
52-Week High | $136.62 | $676.70 |
52-Week Low | $82.57 | $410.74 |
Enterprise Value | $193.69B | $142.24B |
Dividend Yield | 2.63% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Lockheed Martin (LMT) trades at $535.38, down 1.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $627.50. Recent financials show revenue growth to $75.05B in 2025, though net income margin declined to 6.38%. The company announced a $3.45B acquisition of Ultra Maritime to expand naval defense capabilities, and a dividend of $3.45 is scheduled for payment in June 2026.
LMT offers stability through government contracts and dividend growth, but faces risks from execution on recent acquisitions and margin pressure. Analyst sentiment is positive with 57% buy ratings, yet recent earnings misses and rising debt levels warrant caution. The stock presents a long-term opportunity in defense, balanced by near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
